TY - JOUR
T1 - Kidney Biopsy Features Most Predictive of Clinical Outcomes in the Spectrum of Minimal Change Disease and Focal Segmental Glomerulosclerosis
AU - The Nephrotic Syndrome Study Network (NEPTUNE)
AU - Zee, Jarcy
AU - Liu, Qian
AU - Smith, Abigail R.
AU - Hodgin, Jeffrey B.
AU - Rosenberg, Avi
AU - Gillespie, Brenda W.
AU - Holzman, Lawrence B.
AU - Barisoni, Laura
AU - Mariani, Laura H.
AU - Adler, S.
AU - Alter, G.
AU - Athavale, A.
AU - Atkinson, M.
AU - Avila-Casado, C.
AU - Bagnasco, S.
AU - Baker, S.
AU - Barisoni, L.
AU - Bidot, C.
AU - Blake, J.
AU - Bray, M.
AU - Canetta, P.
AU - Chernitskiy, V.
AU - Cooper, A.
AU - Dell, K.
AU - Dell, T.
AU - Derebail, V.
AU - Desmond, H.
AU - Eddy, S.
AU - Fermin, D.
AU - Fervenza, F.
AU - Flynn, P.
AU - Fornoni, A.
AU - Froment, A.
AU - Gadegbeku, C.
AU - Gaut, J.
AU - Gibson, K.
AU - Gillespie, B.
AU - Gipson, D.
AU - Greenbaum, L.
AU - Hewitt, S.
AU - Hingorani, S.
AU - Hladunewich, M.
AU - Hodgin, J.
AU - Hogan, M.
AU - Holzman, L.
AU - Itteera, M.
AU - Jefferson, A.
AU - Kallem, K.
AU - Kaskel, F.
AU - Klida, C.
N1 - Funding Information:
This study was supported by a grant from the National Institutes of Health (NIH)/National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) to L. Barisoni, J.B. Hodgin, L.B. Holzman, L.H. Mariani, and J. Zee (R01-DK118431). L.H. Mariani is supported through funding from the NIH/NIDDK (K08-DK115891). Q. Liu and A. Smith were additionally supported through funding from the NIH/NIDDK (U54-DK083912). The Nephrotic Syndrome Rare Disease Clinical Research Network III (NEPTUNE) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the NIH and led by the National Center for Advancing Translational Sciences (NCATS) through its Office of Rare Diseases Research (ORDR). NEPTUNE is funded under grant number U54DK083912 as a collaboration between NCATS and the NIDDK. Additional funding and/or programmatic support for this project has also been provided by the University of Michigan, NephCure Kidney International, and the Halpin Foundation. All RDCRN consortia are supported by the network's Data Management and Coordinating Center (DMCC; U2CTR002818). Funding support for the DMCC is provided by NCATS and the National Institute of Neurological Disorders and Stroke (NINDS).
Funding Information:
The Nephrotic Syndrome Rare Disease Clinical Research Network III (NEPTUNE) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the NIH and led by the National Center for Advancing Translational Sciences (NCATS) through its Office of Rare Diseases Research (ORDR). NEPTUNE is funded under grant number U54DK083912 as a collaboration between NCATS and the NIDDK. Additional funding and/or programmatic support for this project has also been provided by the University of Michigan, NephCure Kidney International, and the Halpin Foundation. All RDCRN consortia are supported by the network’s Data Management and Coordinating Center (DMCC; U2CTR002818). Funding support for the DMCC is provided by NCATS and the National Institute of Neurological Disorders and Stroke (NINDS).
Funding Information:
This study was supported by a grant from the National Institutes of Health (NIH)/National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) to L. Barisoni, J.B. Hodgin, L.B. Holzman, L.H. Mariani, and J. Zee (R01-DK118431). L.H. Mariani is supported through funding from the NIH/NIDDK (K08-DK115891). Q. Liu and A. Smith were additionally supported through funding from the NIH/NIDDK (U54-DK083912).
Publisher Copyright:
Copyright © 2022 by the American Society of Nephrology
PY - 2022/7
Y1 - 2022/7
N2 - Background Heterogeneity in disease course and treatment response among patients with MCD/FSGS necessitates a granular evaluation of kidney tissue features. This study aimed to identify histologic and ultrastructural descriptors of structural changes most predictive of clinical outcomes in the Nephrotic Syndrome Study Network (NEPTUNE). Methods Forty-eight histologic (37 glomerular, 9 tubulointerstitial, 2 vascular) and 20 ultrastructural descriptors were quantified by applying the NEPTUNE Digital Pathology Scoring System to NEPTUNE kidney biopsies. Outcomes included time from biopsy to disease progression, first complete remission of proteinuria, and treatment response. Relative importance of pathology and clinical predictors was obtained from random forest models, and predictive discrimination was assessed. Results Among 224 participants (34% Black, 24% Hispanic), model performance was excellent, with predictive discrimination of 0.9 for disease progression, 0.85 for complete remission, and 0.81 for treatment response. The most predictive descriptors of outcomes included both conventional-e.g., global sclerosis or segmental sclerosis and interstitial fibrosis/tubular atrophy-and novel features, including adhesion, interstitial foam cells, deflation, periglomerular fibrosis, mononuclear white blood cells, endothelial cell abnormalities, microvillous transformation, and acute tubular injury. Conclusions The most predictive descriptors of clinical outcomes among MCD/FSGS patients reflected structural changes in multiple renal compartments. Reporting these descriptors should be standardized to guide prognostication of proteinuric glomerular diseases.
AB - Background Heterogeneity in disease course and treatment response among patients with MCD/FSGS necessitates a granular evaluation of kidney tissue features. This study aimed to identify histologic and ultrastructural descriptors of structural changes most predictive of clinical outcomes in the Nephrotic Syndrome Study Network (NEPTUNE). Methods Forty-eight histologic (37 glomerular, 9 tubulointerstitial, 2 vascular) and 20 ultrastructural descriptors were quantified by applying the NEPTUNE Digital Pathology Scoring System to NEPTUNE kidney biopsies. Outcomes included time from biopsy to disease progression, first complete remission of proteinuria, and treatment response. Relative importance of pathology and clinical predictors was obtained from random forest models, and predictive discrimination was assessed. Results Among 224 participants (34% Black, 24% Hispanic), model performance was excellent, with predictive discrimination of 0.9 for disease progression, 0.85 for complete remission, and 0.81 for treatment response. The most predictive descriptors of outcomes included both conventional-e.g., global sclerosis or segmental sclerosis and interstitial fibrosis/tubular atrophy-and novel features, including adhesion, interstitial foam cells, deflation, periglomerular fibrosis, mononuclear white blood cells, endothelial cell abnormalities, microvillous transformation, and acute tubular injury. Conclusions The most predictive descriptors of clinical outcomes among MCD/FSGS patients reflected structural changes in multiple renal compartments. Reporting these descriptors should be standardized to guide prognostication of proteinuric glomerular diseases.
UR - http://www.scopus.com/inward/record.url?scp=85133400556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133400556&partnerID=8YFLogxK
U2 - 10.1681/ASN.2021101396
DO - 10.1681/ASN.2021101396
M3 - Article
C2 - 35581011
AN - SCOPUS:85133400556
SN - 1046-6673
VL - 33
SP - 1411
EP - 1426
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
IS - 7
ER -